Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 94
Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulationsJohn A. Reynolds, Ian N Bruce, Eoghan McCarthy et al.|Arthritis Research & Therapy|2018Cited by 68
Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational surveyPintip Ngamjanyaporn, Ian N Bruce, Eoghan McCarthy et al.|Lupus Science & Medicine|2017Cited by 39
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 4
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 3